Novel ADCs from Asia open new clinical opportunities
Phase I–II studies showcase the clinical potential of novel ADCs with enhanced targeting and/or payload strategies
Access to targeted treatments for patients with CUP is still an issue
Studies underline that a tumour-agnostic approach may help improve treatment options
A new claudin 18.2-targeting approach appears promising in gastric cancers
A triple combination investigated in a phase I trial adds to the growing therapeutic options directed at this emerging target
Dual targeted therapy shows promise in mestastatic clear cell renal cell carcinoma
The combination of lenvatinib plus everolimus improved progression-free survival in the LenCabo trial, but toxicity must be carefully assessed
Combination improves endocrine response after CDK4/6 inhibition in ER-positive, HER2-negative advanced breast cancer
In the evERA BC trial, giredestrant plus everolimus led to a prolonged progression-free survival
Data from two novel TEAD inhibitors provide the first evidence for the efficacy and safety of targeted treatments in mesothelioma
In early phase studies, IAG933 and VT3989 led to encouraging disease control rates with manageable toxicity
First-line bemarituzumab improves short-term survival in gastric or gastroesophageal junction cancer overexpressing FGFR2b
Positive initial overall survival data were, however, attenuated and may not be clinically meaningful in a longer-term analysis
Atezolizumab plus a TIGIT inhibitor fails to demonstrate superiority to standard of care in NSCLC
Negative results are reported in SKYSCRAPER-03, while induction immunochemotherapy is investigated as a potential novel approach for unresectable stage II NSCLC
New directions in metastatic mutated NSCLC
Precision targeting, immune modulation and rational trial design are converging to improve patient outcomes
Disitamab vedotin plus immunotherapy almost doubles overall survival in advanced HER2 expressing urothelial cancer
The combination, incorporating the novel antibody–drug conjugate, may transform first-line treatment in the setting, but crucial issues need to be addressed